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Abstract
Pediatric hepatocellular carcinoma (HCC) is rare, resulting in scattered knowledge of tumor
biology andmolecular background. Thus far, the variant in children has been treated as a different
entity from adult HCC. We weigh the hypothesis that HCC in the pediatric and adult groups
may be the same entity and may benefit from the same treatment. Although certain differences
between adult and pediatric HCC are obvious and certain types of HCC may ask for a cus-
tomized approach, in conventional HCC, similarities predominate, warranting treatment aiming
at commonmolecular targets in adult and pediatric HCC patients.
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1 EPIDEMIOLOGY AND ETIOLOGY
Liver cancer comprises 1% to 2% of pediatric solid cancers, making the
liver a rare anatomical site for pediatric cancer.1 Hepatoblastoma and
hepatocellular carcinoma (HCC) are the two most common malignant
liver tumors in children.2 In the United States, the incidence of pedi-
atric HCC is 0.8 to 1.5 permillion.3 In the developingworld, HCC is the
most commonmalignant pediatric liver tumor, although the exact inci-
dence in these regions is unknown.1,2
HCC is the most common primary liver cancer in adults and the
third cause of cancer-related deaths worldwide.4 Particularly in the
Western world, the incidence is rising due to sequela of chronic hep-
atitis C (HCV) and alcoholic and nonalcoholic fatty liver disease.5 The
adult five-year overall survival (OS) rate remains below 12% in the
United States.5 A worldwide survival rate of more than a few months
was not found in the literature. This exceedingly poor outcomemay be
related to frequent detection in advanced stages, no longer amenable
to curative treatment. Furthermore, underlying liver disease may limit
curative treatment options.
Abbreviations: AFP, alpha-fetoprotein; AGR2, anterior gradient 2; APC, adenomatous polyposis coli protein; CASP3, caspase 3; CCNA2, cyclin A2; CCNB1, cyclin B1; CCND1, cyclin D1; CCNE,
cyclin E; CDK4, cyclin-dependent kinase 4; CHIC, Children's Hepatic Tumor International Consortium; CKS2, CDC28 protein kinase 2; COG, Children's Oncology Group; CTNNB1, beta-catenin;
DNA, deoxyribonucleic acid; EKB-569, pelitinib; EPCAM, epithelial cell adhesionmolecule; EPHB2, ephrin type B receptor 2; FL-HCC, fibrolamellar hepatocellular carcinoma; GPOH, German
Society for Pediatric Oncology andHematology; HBV, hepatitis B; HCC, hepatocellular carcinoma; HCN-NOS, hepatocellular neoplasm not otherwise specified; HCV, hepatitis C; HGFR/c-MET
receptor, hepatic growth factor receptor; HGNC, HUGOGeneNomenclature Committee; IL13RA2, interleukin 13 receptor subunit alpha 2; JPLT, Japanese Study Group for Pediatric Liver
Tumors; LAMTOR5, HBVX-interacting protein; LOH, loss of heterozygosity; MTOR, mechanistic target of rapamycin; NFKB1, nuclear factor kappa B; OS, overall survival; PDGFRB, platelet
derived growth factor receptor B; PHITT, Paediatric Hepatic International Tumor Trial; RASA1, RAS p21 protein activator 1; RPS6KB1, ribosomal protein S6 kinase; SIOPEL, Childhood Liver
Tumours Strategy Group; TERT, telomerase reverse transcriptase; TGFA, transforming growth factor, alpha; TGFB1, transforming growth factor beta 1; TKI, tyrosine-kinase inhibitors; TLCT,
transitional liver cell tumor; VEGFA, vascular endothelial growth factor A; VEGFR/KDR, vascular endothelial growth factor receptor
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In Peru, South Africa, and many Asian countries, the introduction
of hepatitis B vaccination programs has caused a decrease in the inci-
dence of pediatric HCC.6–8 Globally, HCC, including its rare histologi-
cally distinct variant fibrolamellar hepatocellular carcinoma (FL-HCC),
occurs mostly in older children and adolescents.9 An earlier claim that
FL-HCC has a more favorable prognosis than conventional HCC could
not be substantiated in a large series by Childhood Liver Tumours
Strategy Group (SIOPEL).10 Despite recent advances in treatment, OS
of pediatric HCC diagnosed in advanced stages remains exceedingly
poor, with five-year percentages of only 17% to 22% for all stages of
pediatric HCC, including FL-HCC, in recent trials from SIOPEL and the
Children's Oncology Group (COG).11,12 Risk factors for pediatric HCC
are conditions that cause hepatocellular damage such as occur in hep-
atitis B (HBV), HCV, autoimmune hepatitis, glycogen storage disease
I–IV, Alagille syndrome, tyrosinemia, Wilson disease, hemochromato-
sis, alpha-1 antitrypsin deficiency, transaldolase deficiency, Gardner
syndrome, familial adenomatous polyposis, Fanconi anemia, ataxia
telangiectasia, primary sclerosing cholangitis, and familial progressive
intrahepatic cholestasis.2 In areas where HBV is endemic, themajority
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of pediatric HCC patients are chronically infected with HBV.2 Impor-
tantly, this does not mean that these tumors develop only in cirrhotic
livers, as activation of the protein LAMTOR5 (HBV X-interacting
protein) or integration of HBV DNA into the hepatocyte genome can
lead to chromosomal instability, suppression of tumor suppressor
genes, and activation of oncogenes and set the stage for development
of HCC.5 For FL-HCC, no epidemiological risk factors are known.10
Pediatric cancers tend to behave differently from adult types, and
some cancer types are specific to the pediatric age group. In part due
to the infrequent occurrence of cirrhosis in children with HCC, pedi-
atric HCC is thus far treated as if the variant in children is a differ-
ent entity from adult HCC.2 The biological background in which pri-
mary liver tumors arise in children and in adults appears similar: in both
patient groups, the disease process is the result of a vicious cycle of
damage and repair, although in most HCCs arising in adults, decades
of chronic hepatic viral infection, alcohol abuse, or nonalcoholic fatty
liver disease result in the end-stage, liver cirrhosis.5
Pediatric tumors,HCC included, appear toneed fewer genetic alter-
ations than adult cancers.13 A possible explanation for the difference
between pediatric and adult tumors is the higher basic cellular growth
rate in pediatric livers.
In this review, we report our search for differences and similari-
ties between pediatric and adult HCC to improve our understanding
of pediatric HCC and to develop a scientifically based rationale for
treatment.
2 HISTOLOGY AND ETIOLOGY
The differentiation grade of HCC in pediatric patients may vary,
although grade within a single tumor is mostly uniform.14 Tumor cells
resemble hepatocytes to a degree that varies according to differen-
tiation stage; they are generally larger than their normal hepatocyte
counterparts.15 Tumor cell nuclei tend to be atypical and irregularwith
abundant mitoses.14
Cycles of damage and repair lead to disruption in related signaling
pathways in HCC, as outlined below. These compounded cycles lead to
hyperplasia, dysplasia, and ultimately HCC.16
Pediatric HCC consists of two broad categories: HCC in the context
of underlying liver disease and de novoHCC.2 De novoHCCmay show
three different histological types: conventional HCC, FL-HCC, or HCC
with elements of hepatoblastoma.
Histology of conventional pediatric HCC is similar to histology in
adults with HCCwithout preexisting liver disease.
FL-HCC is characterized by a histologic appearance of lamellar
stroma that contains large polygonal cells with a deeply eosinophilic
cytoplasm. This may contain pale bodies and hyaline globules, while
the large nuclei often comprise marginalized chromatin and promi-
nent nucleoli.9 Certain molecular components that are aberrantly
expressed in FL-HCC (discussed below) indicate that this tumor could
have its origins in precursor cells of hepatocytes and biliary cells.17
HCC with elements of hepatoblastoma was originally termed tran-
sitional liver cell tumor (TLCT). In TLCT, HCC coexists with elements of
hepatoblastomaand ismost prevalent in adolescents.18 More recently,
any type of HCC/hepatoblastomamixed tumor is by consensus named
“hepatocellular neoplasm not otherwise specified” (HCN-NOS).2,18
3 CYTOGENETIC AND MOLECULAR
BACKGROUND
For pediatric HCC, specific associations between subtypes of his-
tology and prognosis have not been made. Furthermore, discern-
ing HCC from other hepatic tumors, particularly hepatoblastoma, is
not always straightforward. Differentiation can be challenging, espe-
cially when alpha-fetoprotein (AFP), the main diagnostic marker in
hepatoblastoma—yet also a marker of HCC—is low. AFP is secreted
from HCC tumor cells; AFP level correlates with differentiation
rate.15,19 AFPwas elevated in over 90% of HCC patients in a relatively
large recent series of 65patients under20years of age.20 In adultHCC,
AFP was elevated in approximately 70% of patients.19 AFP correlates
with tumor size,19 thus representing an indirect marker for treatment
response.
Research efforts directed at elucidating cytogenetic background
and molecular biology of HCC are discussed in the following sections.
All cytogenetic and molecular aberrations and correlations that will
be discussed are significant findings from the respective cited studies.
HUGO Gene Nomenclature Committee (HGNC)–approved abbrevia-
tions are used throughout.
3.1 Cytogenetic background
Most cases of adult human HCC are aneuploid, suggesting integration
of tumor deoxyribonucleic acid (DNA) and chromosomal instability.
Recurrent gains are reported at 1q, 8q, and20q.21,22 Common losses in
adult HCC are found at 4q, 8p, 13q, 16q, and 17p.21–23 Loss of 8p was
found to be specific for HCC; it did not occur in evaluated FL-HCC (or
hepatoblastoma) cases.23 This locusmay, therefore, contain genes that
cause FL-HCC and/or suppress HCC. The amplified regions of 1q, 6p,
and 17q contain genes with roles in angiogenesis, such as VEGFA (vas-
cular endothelial growth factor A), and in development and differenti-
ation, such as RPS6KB1 (ribosomal protein S6 kinase), while the region
of loss at4qcontains apoptosis-relatedCASP3 (caspase3).24 This latter
loss inhibits apoptosis and, therefore, furthers unlimited growth. Strik-
ingly, when comparing imbalances in adult HCC with those in hepato-
blastoma, gains in chromosomes1, 8, and20are common inboth tumor
types.25–27
Few studies were done on the cytogenetic background of HCC in
the pediatric population specifically. A comparison of nine childhood
and nine adult HBV-positive cases found more frequent loss of het-
erozygosity (LOH)of 13q in pediatricHCCandLOHof8pand17p,with
similar frequencies in pediatric and adult cases.28 Interestingly, 13q
contains the locus of the tumor suppressor gene RB1, which is involved
in cell-cycle control when functional, and is associated with late pro-
gression and more aggressive HCC when disabled.29 Deletion of the
distal part of chromosome 11pwas found in HCN-NOS.13
The combination of gain of chromosome 4q and losses at 9p,
16p, and Xq is specifically found in FL-HCC.23 Although series in
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TABLE 1 Cytogenetic aberrations in adult and pediatric HCC
Locus Adult HCC
Pediatric
HCC HCN-NOS FL-HCC
1q Gain
4q Loss Gain
8p Loss/LOH LOH Normal
8q Gain
9p Loss
11p Partial loss
13q Loss LOH
16p Loss
16q Loss
17p Loss/LOH LOH
20q Gain
Xq Loss
Abbreviations: FL-HCC; fibrolamellar hepatocellular carcinoma; HCC; hep-
atocellular carcinoma; HCN-NOS; hepatocellular neoplasm not otherwise
specified; LOH; loss of heterozygosity.
pediatric HCC and FL-HCC are scarce and small in size, chromosomal
aberrations may provide clues for causative and suppressing genes.
Taken together, these chromosomal imbalances suggest that
aberrations in the growth, development, differentiation, apoptosis,
angiogenesis, and cell-cycle control pathways are at the base of HCC.
This fits well with the observed mechanism of hepatocarcinogenesis;
although there are different types of HCC, generally these tumors are
the result of compounded cycles of damage and repair. Aberrations in
the processes involved in repair ultimately lead to cancer. Cytogenetic
aberrations are summarized in Table 1.
3.2 Molecular background
TheWNT/CTNNB1 (beta-catenin), EPHB2 (ephrin type B receptor 2),
and TGFB1 (transforming growth factor beta 1)/MTOR (mechanistic
target of rapamycin) signaling routes involved in growth, development,
and differentiation are commonly aberrantly activated or repressed in
conventional type pediatric as well as adult HCC.13,16 Furthermore,
angiogenesis and apoptosis pathways are often deregulated.16 Signif-
icantly, aberrant pathways are briefly discussed below. Where avail-
able, findings from pediatric cases are discussed.
3.2.1 Growth, development, and differentiation: The
WNT/CTNNB1, EPHB2, and TGFB1/MTOR signaling routes
WNT/CTNNB1 pathway
The WNT/CTNNB1 pathway is involved in enhancing proliferation
and differentiation of cells. Mutation of CTNNB1 is a major causative
genetic alteration in adult HCC, accounting together with mutation
of TP53 (tumor protein p53; see below) for the two most prevalent
genetic alterations.16,21 Activation ofWNTsignaling is a principal com-
ponent of hepatocarcinogenesis.13 Interestingly, CTNNB1mutation in
adult HCC correlates with absence of underlying liver disease and a
high differentiation grade, which may translate clinically in patients
presenting with larger tumors.30 The absence of underlying liver dis-
ease in these adult tumors may point to parallels with certain cases
of childhood HCC. In pediatric HCC, nuclear CTNNB1 expression was
reported in awell-differentiated tumor;CTNNB1was foundalongwith
E-cadherin expression, and somatic driver mutations in CTNNB1were
reported.31–33 CTNNB1 and TERT (telomerase reverse transcriptase)
promoter mutations occurred in three cases of HCN-NOS.13 The TERT
mutations were exclusive to HCN-NOS and occurred together with
high levels of AFP, suggesting thatHCN-NOS in these cases arises from
HB rather than early-onset HCC. Overall, aberrations in CTNNB1 and
other components of this pathway appear to be connected to tumor
differentiation and form an early and crucial event in hepatocarcino-
genesis.
EPHB2 pathway
The EPHB2 pathway is involved in cellular motility, division, and dif-
ferentiation. EPHB2 expression is associated with disease progression
of HCC in adults.34 RAF1 is found in late stages of HCC. In contrast,
RASA1 (RAS p21 protein activator 1) involvement inHCCwas found in
more differentiated HCC and in early FL-HCC.34 Upregulation of the
c-MET receptor (a.k.a. hepatic growth factor receptor, HGFR) is asso-
ciatedwith vascular invasion and poor prognosis in adultHCC.35 Inter-
estingly, in contrast, a comparison of 10 childhood HCCs with 16 adult
HCC cases, 21 cholangiocarcinomas, and 28 hepatoblastomas showed
that theMET gene was exclusively mutated in pediatric HCC.36 Taken
together, EPHB2 pathway disruptions are reported in both adult and
pediatricHCCandarepredominantly connected to tumorprogression,
likely representing a later phenomenon in hepatocarcinogenesis.
TGFB1/MTOR pathway
The TGFB1/MTOR signaling pathway regulates cellular proliferation,
differentiation, and growth. Loss of the tumor suppressor PTEN cor-
relates with increased levels of phosphorylated AKT1 and MTOR in
adult HCC.37 These aberrations are associated with advanced tumor
grade, increased intrahepatic metastasis, vascular invasion, a higher
TNM stage, and a high MKI67 (a.k.a. Ki-67) index.37 Taken together,
these changes lead touncontrolledprotein synthesis resulting in tumor
growth. No reports from pediatric HCC series were found, indicating
an unexplored field that should be investigated.
3.2.2 Angiogenesis, apoptosis, and cell-cycle control
signaling routes
Angiogenesis pathway
Expression of EGFR, the receptor of TGFA (transforming growth fac-
tor, alpha), was found in 68 of 100 samples of adult HCC exam-
ined and correlated with proliferation, stage, intrahepatic spread,
and tumor differentiation.38 Increased KDR (a.k.a. vascular endothe-
lial growth factor receptor, VEGFR) expression correlates with male
gender, higher tumor differentiation grade, HbsAg positivity, and
cirrhosis.35 Increased PDGFRB (platelet-derived growth factor recep-
tor B) expression is associated with plasma AFP concentration, tumor
size, cirrhosis, and OS.35 In conclusion, increases in expression of
angiogenesis pathway factors are ubiquitous in adult HCC and corre-
late with parameters in all stages of the disease. Strikingly, no pedi-
atricHCC reportswere found, even though the angiogenesis inhibitors
sorafenib and aflibercept are empirically used to treat pediatric HCC.
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Bothdrugshave shownsuccess in small series thus far.39,40 Clearly, this
is an unexplored area of research worthy of attention.
Apoptosis pathway
As previously discussed, mutation of TP53 is highly frequent in adult
HCC. Interestingly, TP53 and CTNNB1 mutations are not common
in FL-HCC.16,30 Hepatocarcinogenesis induced by Aflatoxin-B1 con-
taminated food and HBV is specifically linked to an arginine to serine
substitution at codon 249 of exon 7 of TP53.41 Loss of TP53 and
CDKN2A correlates with advanced stage.42 Deletion of TP53 was
found in HCN-NOS.31 The apoptosis regulator GATA4 was expressed
in childhood HCC, but not in adult HCC.43 As it is also absent from
late fetal and postnatal liver, it may represent amarker in certain cases
of pediatric HCC. Induction of GATA4 is seen especially in patients
with hereditary tyrosinemia type 1.43 Overall, changes in apoptosis
pathway components are linked to adult HCC of variable etiology as
well as to pediatric HCC, although different components are aberrant
in these tumor types. Given their frequency, alterations in this pathway
are likely essential for hepatocarcinogenesis.
Cell-cycle control pathways
Expression of the cell proliferation marker PCNA and the cell-cycle
regulators CDK4 (cyclin-dependent kinase 4), CCNB1 (cyclin B1),
CCNA2 (cyclin A2), and CKS2 (CDC28 protein kinase 2) was found in a
lowsurvival subclass of adultHCC in a gene-expression-profiling effort
in 89 HCCs.44 Deletions of the cell-cycle checkpoint guardian RAD17
were found in HCN-NOS.13 The previously discussed study that com-
pared childhoodandadultHBV-positive cases found lower levels of the
downstreamCTNNB1 targetCCND1 (cyclinD1) in childhoodHCCand
similar levels of CDK4 andCCNE1 (Cyclin E)—which is believed to sub-
stitute for CCND1 function in its absence.28 CCND1 was present in
advanced-stage pediatric HCC in another study.32 As several compo-
nents of these pathways are downstream targets of the major player
CTNNB1, unsurprisingly,many of these factors are themselves dysreg-
ulated in hepatic cancer. Similar to the situation for the apoptosis path-
way, different components are altered according to the type of cancer,
possibly defining the type.
3.2.3 Other pathways aberrant in hepatocarcinogenesis
Transcriptional, translational, and posttranslational
modification pathways
The importance of deregulation of transcription-regulatory compo-
nents was exemplified by mutations in the corepressor GON4L, the
coactivators PRIC285 and SGF29, and the transcription factors MYC,
GATA6, HOXD11, PRDM10, and NFX1 in HCN-NOS.13 With respect to
mutations with a posttranslational effect, the ubiquitin E3 ligase gene
HUWE1was affected.Mutation ofCTNNB1 also has a posttranslational
effect, as it results in dysfunctional phosphorylation sites, prevent-
ing the proteasomal degradation of CTNNB1 via a complex contain-
ingAPC (adenomatous polyposis coli protein).13 Upregulation of genes
involved in ubiquitination and ubiquitination-like pathways was found
in an ominous prognosis subclass of HCC, suggesting etiologic involve-
ment of these signaling routes in disease progression.44 High levels of
thephosphorylated formof transcription factorNFKB1 (nuclear factor
kappa B, subject to ubiquitination) specifically in FL-HCCmay serve as
a diagnostic marker as it is absent from nonneoplastic liver tissue.45
3.2.4 Cellular migration, transformation, and stress
response pathways
Recently, the fusion product of DNAJB1 and PRKACA was detected
as a specific and sensitive marker for FL-HCC, not occurring in
HCC.46 DNAJB1 codes for a heat shock protein active in cellular
stress responses and RPKACA encodes the catalytic domain of pro-
tein kinase A, which regulates a myriad of cellular processes through
phosphorylation.
Furthermore, the hepatobiliary precursor cell markers KRT7, ETFA,
CEACAM5, IL13RA2 (interleukin 13 receptor subunit alpha 2), and
EPCAM (epithelial cell adhesion molecule), and the cellular migration
and transformation component AGR2 (anterior gradient 2), are aber-
rantly expressed in FL-HCC and may assist in distinguishing between
FL-HCC andHCC.17,47
Taken together, despite the limited number and size of molecular
biological studies in pediatric HCC, this overview shows that growth,
development, and differentiation signaling pathways are commonly
aberrant in both pediatric and adult HCC, often in comparable ways.
These pathways are crucial in cell repair, in line with the observed
cycles of damage and repair at the base of HCC. Furthermore, compo-
nents of the angiogenesis, apoptosis, and cell-cycle control pathways
are often dysregulated—albeit differently in the distinct tumor types.
Differences in biological behavior may be defined by the molecular
components that are aberrant in these pathways and whether they
are upregulated, downregulated, or absent. Molecular components in
these pathways are logical targets. Molecular aberrations in pediatric
and adult HCC are summarized in Table 2. Current therapies are
discussed next.
4 CURRENT NONSYSTEMIC TREATMENT
MODALITIES
Irrespective of the underlying molecular changes, HCC diagnosed in
earlier stages may be cured with complete tumor resection with or
without orthotopic liver transplantation, radio-frequency ablation, and
(chemo-) embolization.1,2 Especially in pediatric HCC, the liberal use
of liver transplantation omitting the Milan criteria described for adult
patients is increasingly advocated.48 The Milan criteria comprise as
requirements that the cancerousprocessdoesnot consist ofmore than
one solitary nodule with a maximum diameter of five centimeters, or
three nodules measuring each maximally three centimeters, and that
novascular invasionor extrahepaticmanifestation is present.49 ForFL-
HCC, the only effective treatment is complete resection.10
5 TARGETED THERAPIES IN CLINICAL
TRIALS
The aforementioned treatmentmodalities rarely yield lasting results in
advanced or recurring HCC. Although many agents have been devel-
oped and tested, efficacious chemotherapeutic options are limited.
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TABLE 2 Molecular aberrations in adult and pediatric HCC
Pathway Molecular component Adult HCC Pediatric HCC HCN-NOS FL-HCC
WNT/CTNNB1
CTNNB1 Δ Δ Δ None
CTNNB1 +/++ +/++
E-cadherin +
TERT Δ
EPHB2 +
RAF1 +
RASA1 + +
HGFR ++
MET Δ
TGFB1/MTOR
PTEN -
AKT1 ++
MTOR ++
Angiogenesis
EGFR +
TGFA
VEGFR ++
PDGFRB ++
Apoptosis
TP53 Δ/— — None
CDKN2A —
GATA4 - +
Cell-cycle control
PCNA +
CDK4 + +
CCNB1 +
CCNA2 +
CKS2 +
RAD17 —
CCND1 –/+
CCNE1 + +
Transcriptional/translational/
posttranslational modification
GON4L Δ
PRIC285 Δ
SGF29 Δ
MYC Δ
GATA6 Δ
HOXD11 Δ
PRDM10 Δ
NFX1 Δ
HUWE1 Δ
NFKB1 ++
Cell migration/transformation/
stress response
DNAJB1/RPKACA - +
(Continues)
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TABLE 2 (Continued)
Pathway Molecular component Adult HCC Pediatric HCC HCN-NOS FL-HCC
KRT7 ++
ETFA ++
CEACAM5 ++
IL13RA2 ++
EPCAM ++
AGR2 ++
Δ, Mutation;++, upregulation;+, expression/presence; -, absence; –, downregulation; —, loss.
Abbreviations: AGR2, anterior gradient 2; CCNA2, Cyclin A2; CCNB1, Cyclin B1; CCND1, Cyclin D1; CCNE1, Cyclin E; CDK4, cyclin dependent kinase 4;
CKS2, CDC28 protein kinase 2; CTNNB1, beta-catenin; EGFR, endothelial growth factor receptor; EPCAM, epithelial cell adhesionmolecule; EPHB2, ephrin
typeB receptor 2; FL-HCC, fibrolamellar hepatocellular carcinoma;HCC, hepatocellular carcinoma;HCN-NOS, hepatocellular neoplasmnot otherwise spec-
ified; HGFR, hepatic growth factor receptor; IL13RA2, interleukin 13 receptor subunit alpha 2; MET, mesenchymal to epithelial transition; MTOR, mecha-
nistic target of rapamycin; NFKB1, Nuclear Factor kappa B; PDGFRB, platelet derived growth factor receptor B; RASA1, RAS p21 protein activator 1; TERT,
telomerase reverse transcriptase; TGFA, transforming growth factor, alpha; VEGFR, vascular endothelial growth factor receptor.
TABLE 3 Current targeted therapies in adult HCC
Prime
target→ agent ↓ VEGFA PDGFRB
RAF1/MAP2K2/
EPHB2 EGFR
PIK3CA/
AKT1/MTOR
MET/
HGF HSP90AA1
FGF1/
HPSE
TNFRSF
10A
Sorafenib X X X
Regorafenib X X X
Aflibercept X X
Sunitinib X X
Brivanib X X
Bevacizumab X X
Ramucirumab X X
TSU-68 X X
Linifanib X X
Cediranib X X
Pazopanib X X
Lenvanib X X
Lenalidomide X X
Axitinib X X
Erlotinib X
Gefitinib X
Lapatinib X
Cetuximab X
Everolimus X
Temsirolimus X
Sirolimus X
Rapamycin X
Selumetinib X
Refametinib X
Tivantinib X
Cabozantinib X
Ganetespib X
PI-88 X
Mapatumumab X
Abbreviations: EGFR, endothelial growth factor receptor; EPHB2, ephrin type B receptor 2; FGF1, fibroblast growth factor 1; HCC, hepatocellular carci-
noma;HGF, hepatic growth factor;HPSE, heparanase;HSP90AA1, heat shockprotein 90alpha family classAmember1;MAP2K2,mitogen-activatedprotein
kinase 2;MET, mesenchymal-to-epithelial transition;MTOR,mechanistic target of rapamycin; PDGFRB, platelet-derived growth factor receptor B; PIK3CA,
phosphatidylinositol-4,5-bisphophate 3-kinase catalytic subunit alpha; TNFRSF10A, tumor necrosis factor receptor superfamily member 10A; VEGFA, vas-
cular endothelial growth factor receptor.
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TABLE 4 Current targeted therapies in pediatric HCC
Prime target→ agent ↓ VEGFA PDGFRB RAF1/MAP2K2/EPHB2 CTNNB1 CCND1 NFKB1
Sorafenib X X X
Aflibercept X X
Curcumin X X X
Abbreviations: CCND1, Cyclin D1; CTNNB1, beta-catenin; EPHB2, ephrin type B receptor 2; HCC, hepatocellular carcinoma; MAP2K2, mitogen-activated
protein kinase 2; NFKB1, nuclear factor kappa B; PDGFRB, platelet-derived growth factor receptor B; VEGFA, vascular endothelial growth factor receptor.
From the wide array of molecular players implicated in hepatocarcino-
genesis, a number of attractive targets in humanHCChave been estab-
lished. Agents targeting these actors include tyrosine-kinase inhibitors
(TKI) with names ending in “nib” and monoclonal antibodies with
names ending in “mab.” Currently used agents and their targets in adult
HCC are displayed in Table 3.24,30,40,50,51
A recent meta-analysis of targeted agents used in advanced
adult HCC shows that sorafenib combined with erlotinib may be
the most effective regimen.42,51,52 Current chemotherapeutic treat-
ment of adult patients with advanced HCC (and an otherwise
decent performance status) consists of sorafenib or a sorafenib-based
regimen.42,51,52 In a small retrospective study, the German Society
for Pediatric Oncology and Hematology (GPOH) added sorafenib on
a “compassionate use” base to cisplatin and doxorubicin in pediatric
HCC, with promising results (6 of 12 patients were in complete remis-
sion after a median follow-up of 20 months).39 A prospective phase
III trial evaluating the efficacy of sorafenib in relapsed or refractory
pediatric HCC is currently run by COG. However, acquired resis-
tance to sorafenib is an important issue. The second-generation TKI
EKB-569 (pelitinib), which, in addition to EGFR and KDR, also targets
ERBB2 (a.k.a. HER2NEU), shows promise in multi-drug-resistant cells
in vitro.53 A synergistic effect was observed in highly resistant cells
when a combination of EKB-569 and sorafenib was applied.
Stable disease in a pediatric HCC patient was seen in a phase I
trial of the VEGF-trapping agent aflibercept.40 Worth mentioning is
the preliminary promise of curcumin in pediatric HCC cell lines and
orthotopic models.54 This phytochemical with few side effects in adult
patients has shown antitumor effects in adult HCC. NFKB1, CTNNB1,
and CCND1 are its molecular targets. All of these targets have
significant roles in pediatric HCC as described above. Targeted ther-
apies with potential efficacy in pediatric HCC are shown in Table 4.
Combining drugs to enhance the effects of sorafenib, while tar-
geting multiple molecular pathways at once, may at present be the
approach of choice in advanced HCC. However, currently available
treatments lead to stable disease (tumor necrosis, no decrease in size)
at best and should thus be regarded as palliative treatment with only
modest gain in survival and quality of life.42,51
6 CONCLUSION AND WAY FORWARD
Rather than a divide in pediatric and adult HCC, there appears to be
a distinction in HCC types based on origination in healthy liver or
liver compromised by inflammatory or metabolic disease. Taking the
commonly aberrant WNT/CTNNB1 pathway as an example, mutation
or increased expression of CTNNB1 is reported in well-differentiated
HCC without underlying inflammatory liver disease in both adult and
pediatric patients. Types of HCCmay thus be characterized by theway
in which signaling pathway components are altered.
Given the epidemiology, most data are generated from adult HCC
patients. Pronounced aberrations of the angiogenesis pathway were
found in certain adult HCC cases and may be related to cirrhosis.32
No data on angiogenesis signaling in pediatric HCC are available.
Even without these data, we argue that for a strategy treatment to
be effective, the type of HCC and its molecular changes rather than
the age group matters. Thus, the most successful treatment strategies
based on recurrent molecular abnormalities obtained from adult
patients may be effective in certain pediatric patients. The efficacy of
the angiogenesis inhibitor sorafenib in adults and its early promise in
pediatric patients exemplifies this approach.36
Furthermore, international collaboration initiatives, such as Chil-
dren's Hepatic Tumor International Consortium (CHIC) and the
upcoming Paediatric Hepatic International Tumor Trial (PHITT), are
essential for progress in pediatricHCCgiven the low incidenceof these
tumors.2,10 These initiatives may allow for a research effort to define
the molecular aberration profiles at the origin of the different HCC
tumor types to facilitate the search for effective targeted agents.
In conclusion, the molecular background of the diverse HCC types
needs tobe further elucidated.Apart fromspecific typesofHCC,which
predominantly occur in older pediatric and adolescent patients (HCC
in patients with underlying liver diseases or with familial cancer syn-
dromes; FL-HCC or HCN-NOS), too few arguments currently remain
for a distinction in treatment of HCC based on age group.
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